T-lymphocyte activation antigen CD86 (CD86) (CD86)

T-lymphocyte activation antigen CD86 (CD86) mRNA is the transcript encoding a vital co-stimulatory protein expressed on antigen-presenting cells such as B cells, dendritic cells, and macrophages. The resulting CD86 protein interacts with CD28 on T cells to provide the essential second signal for activation, while its interaction with CTLA-4 provides inhibitory signals to maintain immune homeostasis (UniProt P42081). In therapeutic development, CD86 mRNA is a focal point for both silencing and expression strategies; for instance, siRNA-mediated knockdown of CD86 mRNA is explored to induce immune tolerance in transplantation (PubMed 18430778), while mRNA-based vaccines may incorporate CD86 sequences to enhance the immunogenicity of tumor cells (PubMed 31434684). Dysregulation of CD86 expression is linked to autoimmune diseases like rheumatoid arthritis and various cancers where it facilitates immune evasion (NCBI Gene 942). Clinically, the CD86 pathway is most commonly modulated by protein-level inhibitors such as Abatacept and Belatacept, which compete with CD28 for binding (PubMed 15634878). Monitoring CD86 mRNA levels serves as a potential biomarker for assessing the activation state of the immune system in inflammatory and oncological contexts.

Other names

B7-2B7.2B70CD28LG2LAB72FUN-1

Competitive inhibition of CD28 binding by acting as a CTLA-4-Ig fusion protein or direct antibody blockade, thereby preventing the costimulatory signal required for T-cell activation.